News

60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study

  • 60 Degrees Pharma begins enrolling patients for a tafenoquine babesiosis trial at Yale, Tufts, and Rhode Island Hospital, with results expected Sept., 2025
    07/19/2024

Why Is 60 Degrees (SXTP) Stock Up 56% Today?

  • 60 Degrees (NASDAQ: SXTP ) stock is on the rise Friday alongside heavy early morning trading of the specialty pharmaceutical company's shares. This has more than 12.5 million shares of SXTP stock being traded as of this writing.
    07/19/2024
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

60 Degrees Pharmaceuticals, Inc. (SXTP) can buy. Click on Rating Page for detail.

The price of 60 Degrees Pharmaceuticals, Inc. (SXTP) is 0.4304 and it was updated on 2024-07-19 09:01:01.

Currently 60 Degrees Pharmaceuticals, Inc. (SXTP) is in undervalued.

News
    
News

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment

  • WASHINGTON, July 09, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced ethics approval of an open label, expanded access study of the ARAKODA® regimen of tafenoquine in combination with standard of care regimens in immunosuppressed patients with persistent/relapsing babesiosis. The goal of the study is to confirm the findings of an 80 percent babesiosis cure rate in humans observed in a similar population in an earlier case series of tafenoquine completed by Yale School of Public Health (YSPH) in April 2024 and published in the journal, Clinical Infectious Diseases.
    Tue, Jul. 09, 2024

First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind

  • 60 Degrees Pharmaceuticals enrolls first patient in a clinical study at Tufts to assess safety and efficacy of tafenoquine in treating acute babesiosis.
    Thu, Jun. 27, 2024

Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind

  • 60 Degrees Pharmaceuticals has entered an agreement with Tufts Medical Center to conduct a clinical trial that will evaluate the safety and efficacy of tafenoquine for the treatment of babesiosis in humans The study will be the world's first clinical trial to evaluate tafenoquine in human babesiosis patients Enrollment will begin after a site initiation visit in Boston on June 13, 2024 Agreements are being negotiated with two other prominent university hospitals to expand recruitment in the Northeast U.S. where the incidence of babesiosis has been increasing; babesiosis, a tick-borne and potentially life-threatening illness, is an orphan disease Case studies in the medical literature suggest that tafenoquine may be a promising alternative for the treatment of some patients hospitalized with relapsing babesiosis WASHINGTON, May 30, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today it has entered into an agreement with Tufts Medical Center in Boston to conduct the world's first clinical trial evaluating the efficacy and safety of tafenoquine in treating human babesiosis patients. Recruitment of at least 24 hospitalized patients diagnosed with babesiosis will begin after a site initiation visit at Tufts Medical Center on June 13, 2024.
    Thu, May. 30, 2024

60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study

  • 60 Degrees Pharmaceuticals funds a study at NC State to test for Babesia spp in chronic fatigue patients, aiming to link these infections to CFS symptoms.
    Mon, May. 20, 2024

60 Degrees Pharmaceuticals, Inc. to Post Q2 2024 Earnings of ($0.33) Per Share, HC Wainwright Forecasts (NASDAQ:SXTP)

  • 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP – Free Report) – HC Wainwright lowered their Q2 2024 earnings per share (EPS) estimates for 60 Degrees Pharmaceuticals in a research report issued on Thursday, May 16th. HC Wainwright analyst E. White now expects that the company will post earnings per share of ($0.33) for the quarter, down from their prior forecast of ($0.07). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for 60 Degrees Pharmaceuticals’ current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for 60 Degrees Pharmaceuticals’ Q3 2024 earnings at ($0.12) EPS, Q4 2024 earnings at ($0.12) EPS, FY2024 earnings at ($0.56) EPS, FY2025 earnings at ($0.11) EPS and FY2026 earnings at ($0.04) EPS. 60 Degrees Pharmaceuticals Trading Up 0.9 % Shares of NASDAQ SXTP opened at $0.22 on Monday. The firm has a market cap of $2.76 million and a P/E ratio of -0.22. 60 Degrees Pharmaceuticals has a 1-year low of $0.20 and a 1-year high of $8.65. The business’s 50 day moving average is $0.25 and its 200-day moving average is $0.49. 60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) last announced its earnings results on Monday, April 1st. The company reported ($0.44) earnings per share for the quarter. The firm had revenue of ($0.10) million during the quarter, compared to the consensus estimate of $0.06 million. About 60 Degrees Pharmaceuticals (Get Free Report) 60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. Read More Five stocks we like better than 60 Degrees Pharmaceuticals Dividend Capture Strategy: What You Need to Know MarketBeat Week in Review – 5/13 – 5/17 Buy P&G Now, Before It Sets A New All-Time High Take-Two Interactive Software Offers 2nd Chance for Investors What Investors Must Know About Over-the-Counter (OTC) Stocks Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
    Mon, May. 20, 2024
SEC Filings
SEC Filings
Press Releases
StockPrice Release
More Headlines
News

60 Degrees Pharmaceuticals Announces First Quarter 2024 Results

  • Q1 2024 net product revenues increased 515% year-over-year to $105.7 thousand. Gross profit increased from ($55.9 thousand) to $51.0 thousand.
  • 05/15/2024

60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases

  • 60 Degrees Pharma plans clinical trial of Tafenoquine for Babesiosis. Letter to Journal of Infectious Diseases outlines protocol. Enrollment starts summer.
  • 05/08/2024

60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required

  • Trial planning and execution to proceed as planned WASHINGTON, May 02, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc.  (NASDAQ: SXTP ; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has provided comments on the protocol of a planned clinical trial that will study the use of tafenoquine in treating babesiosis. Babesiosis, a potentially life-threatening disease in immunosuppressed patients, is a tick-borne illness steadily emerging in the United States.
  • 05/02/2024

60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis

  • 60 Degrees Pharma (Nasdaq: SXTP) will sponsor a study using tafenoquine, an FDA-approved malaria drug, to treat canine babesiosis, a tick-borne disease.
  • 04/03/2024

60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024

  • 60 Degrees Pharma advises of expected FDA response a month later than anticipated. Prepares for June 1, 2024, start of trial of tafenoquine for babesiosis.
  • 03/14/2024

60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris

  • Candida auris (C. auris) is a dangerous drug-resistant fungal pathogen emerging in U.S. hospitals Tafenoquine's presumed mode of action against C.
  • 02/20/2024

60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer

  • Kristen Landon appointed Chief Commercial Officer at 60 Degrees Pharma leading ARAKODA® relaunch for malaria prevention and expanded tick-borne strategy.
  • 02/08/2024

WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering

  • JERSEY CITY, N.J. , Jan. 31, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that 60 Degrees Pharmaceuticals, Inc., ("60P," NASDAQ: SXTP; SXTPW) specialists in developing and marketing medicines for infectious diseases, has completed its previously announced Public Offering of 5,260,901 units (the "Units") at a price to the public of $0.385 per Unit and 999,076 pre‑funded units (the "Pre‑Funded Units") at a price to the public of $0.375 per Pre‑Funded Unit.
  • 01/31/2024

60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering

  • WASHINGTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals , Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), specialists in developing and marketing new medicines for the treatment and prevention of infectious diseases, announced today the closing of its public offering of 5,260,901 units (the “Units”) at a price to the public of $0.385 per Unit and 999,076 pre-funded units (the “Pre-Funded Units”) at a price to the public of $0.375 per Pre-Funded Unit. Each Unit consists of one share of common stock and one warrant exercisable for one share of common stock (the “Warrant”).
  • 01/31/2024

PDD Stock Alert: Morgan Stanley Is Losing Faith in Temu

  • PDD (NASDAQ: PDD ) stock is slipping on Tuesday after Morgan Stanley's analysts provided a sour look at the company's Temu e-commerce app. This new coverage comes from Morgan Stanley analysts Simeon Gutman and Brian Nowak in a note to clients.
  • 01/30/2024

WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering

  • JERSEY CITY, N.J. , Jan. 30, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that 60 Degrees Pharmaceuticals, Inc. ("60P"), (NASDAQ: SXTP; SXTPW) specialists in developing and marketing medicines for infectious diseases, announced today the pricing of its public offering of 5,260,901 units (the "Units") at a price to the public of $0.385 per Unit and 999,076 pre‑funded units (the "Pre‑Funded Units") at a price to the public of $0.375 per Pre‑Funded Unit.
  • 01/30/2024

60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering

  • 60 Degrees Pharma announces a $2.4 mil public offering, with funds to be used for working capital, relaunching ARAKODA for malaria prevention, and research
  • 01/30/2024

Why Is 60 Degrees (SXTP) Stock Down 33% Today?

  • 60 Degrees (NASDAQ: SXTP ) stock is falling on Tuesday after the specialty pharmaceutical company's public offering went into effect. 60 Degrees originally revealed plans for a public offering last week with its intention to enact it as soon as possible.
  • 01/30/2024

60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting

  • Post-FDA meeting, 60 Degrees Pharma plans pivotal study of tafenoquine in hospitalized babesiosis patients, aiming to start in summer 2024. #biotech #SXTP
  • 01/22/2024

60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements

  • WASHINGTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that on January 10, 2024 it received written notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) stating the Company has regained compliance with the minimum bid price requirement (the “Minimum Bid Price Requirement”), as set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. The Company had been notified by Nasdaq on November 2, 2023 that it was not in compliance with the Minimum Bid Price Requirement because its common stock had failed to maintain a minimum bid price of $1.00 for 30 consecutive business days.
  • 01/16/2024

60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024

  • 60 Degrees Pharma has received IRB approval for a Phase IIA study evaluating tafenoquine's efficacy in treating hospitalized babesiosis patients, while the
  • 12/26/2023

60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease

  • Type C meeting will be to discuss a proposed Phase II study of tafenoquine for treatment of babesiosis Transmitted by ticks, babesiosis is a life-threatening parasitic disease increasing in frequency in the United States Meeting with FDA scheduled for January 15, 2024 WASHINGTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted a Type C meeting with the Company to consult on the path forward in developing the tafenoquine regimen of ARAKODA® for a potential indication in treating hospitalized babesiosis patients. The meeting will take place on January 15, 2024.
  • 11/15/2023

60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in Boston

  • 60 Degrees Pharma Presents Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting
  • 10/19/2023

60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases

  • FDA advice to Company suggested execution of ACLR8-LR, a placebo-controlled Phase IIB study of tafenoquine in COVID-19 patients, may not be feasible in the U.S. Company will therefore focus efforts on further commercialization related to ARAKODA® (tafenoquine) for prophylaxis of malaria, and prepare for a Phase IIA study of tafenoquine in hospitalized babesiosis patients Company is preparing for submission of a pre-IND meeting request with FDA for babesiosis in the current fourth quarter of 2023, and plans to appoint a chief commercial officer to lead ARAKODA commercialization WASHINGTON, Oct. 12, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced that its subsidiary, 60P Australia Pty Ltd, will not re-submit its investigational new drug application (“IND”) for ACLR8-LR, a Phase IIB study of tafenoquine compared to placebo in patients with mild to moderate COVID-19 disease and low risk of disease progression. Tafenoquine is the active molecule in ARAKODA ® , the Company's U.S. Food and Drug Administration (FDA)-approved regimen for malaria prevention.
  • 10/12/2023

60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements

  • WASHINGTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (“60P”) (NASDAQ: SXTP), specialists in developing and marketing medicines for infectious diseases, today announced that 60P Australia Pty Ltd, a majority-owned subsidiary of 60P, has withdrawn its investigational new drug (IND) application for ACLR8-LR, a Phase IIB study of the use of tafenoquine in treating COVID-19, and intends to submit a new IND in the fourth quarter.
  • 09/18/2023

60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment Conference

  • WASHINGTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals Inc. (“60P” or the “Company”) (Nasdaq: SXTP ), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that CEO Dr. Geoff Dow and CFO Ty Miller will participate in the H.C. Wainwright 25th Annual Global Investment Conference  September 11-13, to be held in New York City.
  • 09/06/2023

Why Is 60 Degrees Pharmaceuticals (SXTP) Stock Up 17% Today?

  • 60 Degrees Pharmaceuticals (NASDAQ: SXTP ) stock is on the rise Thursday following the company's public debut yesterday. The public launch of SXTP stock saw the company offering up 1,415,095 units at a price of $5.30 each.
  • 07/13/2023
Unlock
SXTP Ratings Summary
SXTP Quant Ranking